Reviews/Vitamin B12/Oral vitamin B12 matches injection
Deficiency And Status · VITB12-STATUS-03 · v2
Several direct trials compared swallowing high-dose vitamin B12 against getting it by injection in people who were deficient. On the simple question of how many patients returned to a normal blood level, high-dose oral tablets matched injections in adults over a few months ([3],[11], and [7] at week 8). But two trials that tested oral against injection under a formal 'no worse than' rule found oral did not clear that bar ([18], and [7] at week 52), and injections produced a bigger rise in the blood markers. In children with anemia, injections worked clearly better than tablets ([15]). So the panel read the plain, unqualified claim as too strong: oral looks equal for restoring normal levels in adults at high doses, but not across every population or every measure.
On the proportion of deficient adults brought back to a normal serum level, high-dose oral supplementation matched injection: [3] reported normalization in all patients (100%) in both arms, [11] found B-12 'normalized in all individuals' with no significant between-group difference, and [7] reported both arms 'well above 90%' at week 8 with oral 'no less effective than IM administration at 8 weeks'. Against strict equality, [18] states 'the primary hypothesis that oral VB12 treatment would be noninferior to IM treatment was rejected', and [7] gave week-52 non-inferiority probabilities of 0.036 (PPT) and 0.060 (ITT). In children, [15] found the rise in serum B12 (P=0.016) and hemoglobin (P=0.001) significantly greater with parenteral treatment. Where a functional nerve outcome was measured, injection outperformed tablets [14], and [1] shows oral normalization needs a dose more than 200 times the recommended dietary allowance. The contested point: The division is over what 'corrects as effectively' means: judged as the share of adults reaching a normal level, oral matches injection ([3],[11],[7] at week 8), but judged by a formal non-inferiority test or by the magnitude of biomarker and functional response, injection leads ([18],[7] at week 52,[14],[15]). The pediatric trial [15] pulls further against equivalence, showing the finding does not generalize across populations.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin B12, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The unqualified 'as effectively' is directly contradicted by two head-to-head trials: Metaxas [18] formally rejected non-inferiority of oral, and OB12 [7] gave a non-inferiority probability below 0.06 at 52 weeks, both favoring IM.
The claim is population-blind: in children with macrocytic anemia [15], parenteral produced significantly greater serum B12 (P=0.016) and hemoglobin (P=0.001) rises, so equivalence does not generalize across populations.
Where it remains uncertain. Two head-to-head trials rejected non-inferiority of oral ([18]; [7] at week 52), and parenteral was significantly superior in children [15] and on a nerve-repair outcome [14].
Aleatory
Several head-to-head trials are small ([3] 50 patients, [11] 50 patients, [18] 37 patients), so estimated between-route differences carry wide sampling variability.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct head-to-head equivalence on serum cobalamin normalization in adults with low levels.
“Both the oral and IM formulations were effective in restoring normal levels of serum cobalamin in all patients studied (100%).”
Panel auditInternal validity: medium · scope of inference: Selected patients with low cobalamin but otherwise healthy, treated for 3 months.Key limitations: open-label · small sample · proprietary oral formulation · one MMA endpoint favoured oral at day 91
Largest trial; supports short-term non-inferiority for repletion in the elderly.
“Although differences were found between administration routes at week 52, the probability that the differences were below the non-inferiority threshold was very low.”
Panel auditInternal validity: high · scope of inference: Patients ≥65 with B12 deficiency in primary care over up to 52 weeks.Key limitations: non-inferiority not met at week 52 · 20% loss to follow-up · open route inevitably unblinded
Supports equivalence even in a malabsorptive (post-RYGB) population.
“The efficacy of oral vitamin B-12 supplementation was similar to that of hydroxocobalamin injections in the present study.”
Panel auditInternal validity: medium · scope of inference: Post-Roux-en-Y gastric bypass patients with subnormal B12 over 6 months.Key limitations: small sample · single surgical population · no formal non-inferiority margin reported
Population-specific counter-evidence: parenteral superior in children.
“Increase in serum vitamin B12 levels and hemoglobin was better in children with nutritional macrocytic anemia receiving parenteral as compared to oral vitamin B12.”
Panel auditInternal validity: medium · scope of inference: Children 2 months–18 years with nutritional macrocytic anaemia over 3 months.Key limitations: open-label · all received initial parenteral dose · paediatric nutritional deficiency only
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct human head-to-head RCTs are genuinely split, with the largest and pediatric trials weighing against strict equivalence, so the claim as stated warrants an Uncertain verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Long-term head-to-head durability. Equivalence holds short-term but breaks at week 52 in [7]; whether oral sustains repletion over years is unresolved. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A multi-year randomized non-inferiority trial of high-dose oral versus IM with normalization assessed at 12 and 24 months.
Open question: Does high-dose oral B12 remain non-inferior to IM for maintaining normal levels beyond one year? Why it is still open: [7] met non-inferiority at week 8 but failed it at week 52, and no trial extends further.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19